UK-based biotechnology company Minaris Advanced Therapies has launched a new GMP facility in Munich, Germany, enhancing its global manufacturing network.
The new facility, located in Taufkirchen, aims to strengthen Minaris’ role in advancing cell and gene therapies from concept to commercialisation.
The strategic expansion underscores the company’s commitment to supporting technology transfer of commercial advanced therapies into Europe.
The new facility builds on Minaris’ decade-long experience in clinical and commercial manufacturing of advanced therapies.
It consolidates process and analytical development and legacy manufacturing operations into a single site.
Minaris Advanced Therapies CEO Orla Cloak said: “The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally.
“It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability.”
The new facility is located close to Munich International Airport, which provides logistical advantages for clients across Europe and beyond.
It features six Grade B/A cleanrooms for aseptic manufacturing, a Grade C cleanroom for bioreactors and closed systems, and 2,411 ft2 of expansion space.
Each cleanroom suite has independently controlled HVAC systems to minimise downtime and enable parallel production activities.
The site also includes dedicated process development and quality control laboratories, cryopreservation and storage facilities, and enhanced safety systems.
Based in Philadelphia, Pennsylvania, Minaris is a contract development and manufacturing organisation (CDMO) focusing on cell and gene therapies.
Minaris Advanced Therapies is part of Altaris, an investment firm focused on healthcare industry companies.
Minaris Advanced Therapies board chairman Iain Baird said: “This facility embodies our shared vision for the future of cell and gene therapy manufacturing—scalable, flexible, and globally integrated.
“The seamless transition into this new facility is a testament to the dedication of our team in Germany and the commitment Minaris Advanced Therapies has to bring long-term value to clients and patients worldwide.”
